News & Publications

NEWS & PUBLICATIONS

Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

Nomination Call for the 2012 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery

2012 Jan 12 |
Category: News, Technology

Barcelona, January 12, 2012 – Prous Institute for Biomedical Research is proud to announce the nomination call for the 2012 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery. Following their tradition of drug discovery science and technology, Prous Institute has donated the award biennially since 2004, acknowledging outstanding achievements in the field of medicinal chemistry. This year’s award will be given at the XXII EFMC "International Symposium on Medicinal Chemistry" (EFMC-ISMC) to be held in Berlin, Germany on September 2-6, 2012. The deadline for nominations is January 31, 2012.

More About the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery

This award was established to encourage innovation and investigation in technologies related to drug discovery. The award consists of € 7,500, a diploma, and an invitation to give a lecture at the upcoming EFMC-ISMC International Symposium on Medicinal Chemistry.

The requirements for a nomination for the Prous Institute-Overton and Meyer Award, are: a nomination letter, a brief CV including a list of selected publications and two supporting letters. The nomination should be submitted to the Chairman of the Juries, Dr Hans Ulrich Stilz, President of EFMC, c\o EFMC Administrative Secretariat, Rue Michel de Ghelderode 33/2, 1348 Louvain-la-Neuve, Belgium / Fax: +32 10 45 97 19 / Email: awards@efmc.info. More information and submission details are available on www.efmc.info

About Prous Institute for Biomedical Research

Prous Institute for Biomedical Research is a privately owned drug discovery company located in Barcelona. Prous Institute was founded by Dr. J.R. Prous in 2000 with the goal of discovering new drugs using computational tools and methods (SYMMETRY®) to predict drug safety and efficacy, alongside expertise in organic synthesis and laboratory and animal studies. J.R. Prous is highly experienced in drug discovery and was the founder, CEO and President of Prous Science (1965-2007), the originator of the well-known MDDR and Integrity databases. Prous Science was acquired by Thomson Reuters in 2007.

For more information, please contact Prous Institute:

E-mail: info@prousresearch.com, Tel: 0034 93 457 17 95, or visit www.prousresearch.com